Hints and tips:
Related Special Reports
...That is the case in the Moderna melanoma trial....
...Bausch & Lomb, the eyecare unit of the company formerly known as Valeant Pharmaceuticals, had aimed to raise up to $840mn in what was the second-largest listing of the year....
...Bausch & Lomb, the eyecare unit of the company formerly known as Valeant Pharmaceuticals, had been aiming to raise up to $840mn, on Thursday evening but eventually sold at $18 per share, raising $630mn....
...Worse, Bausch Health — formerly known as Valeant Pharmaceuticals — paid $2.4bn more for it back in 2013....
...After three years of losses between 2015 and 2017 driven by a disastrous investment in Valeant Pharmaceuticals, Pershing Square has become one of the hedge fund industry’s top performers....
...IPO Shares in Bausch & Lomb, the eyecare unit of the company formerly known as Valeant Pharmaceuticals, begin trading today in New York after yesterday pricing its initial public offering below its target...
...as a major shareholder of Valeant Pharmaceuticals....
...Pharmaceuticals....
...Under Mr Pearson, a former McKinsey consultant known for his aggressive cost-cutting strategy, Valeant went from being a small speciality pharmaceutical company to a branded drugs conglomerate with a market...
...Hempton, known for his bets against companies such as Valeant Pharmaceuticals and Wirecard, raised concerns about the level of insurance extended to Greensill by IAG, calling it “potentially a solvency risk...
...After a 40 per cent gain in 2014, Mr Ackman suffered a run of bad bets, mostly notably on pharmaceutical group Valeant and a bet against nutritional supplement seller Herbalife, which led to four consecutive...
...And John Hempton of Bronte Capital, known for his bets against companies such as Valeant Pharmaceuticals and Wirecard, said he raised concerns about Greensill with Australia’s financial regulator in November...
...Mr Ackman is enjoying a big turnround in his fortunes after four consecutive years of losses that included bad bets on pharmaceuticals group Valeant and a bet against nutritional supplement seller Herbalife...
...Bill Ackman lost $1bn of his $2.6bn personal net worth in one year after taking a significant position in Valeant Pharmaceuticals....
...We didn’t even mention Valeant, the unsavoury hedge fund hotel pharmaceutical blow-up which ValueAct held board seats in after investing $200m back in 2006....
...Pershing faced major setbacks from a bet on Valeant Pharmaceuticals that cost the firm $4bn and an ill-fated $1bn short against the diet drinks marketing company Herbalife....
...The most recent boom and bust came five years ago when shares in pharmaceutical maker Bausch Health Companies, then known as Valeant, collapsed amid price-fixing and accounting scandals....
...Mr Boze is board chair of CBRE Group and a director of Trinity Industries, and a former director of Valeant Pharmaceuticals....
...But one narrative cut through the noise: Valeant had gone spectacularly awry under unusual leadership....
...Bausch Health, which rebranded from Valeant Pharmaceuticals almost two years ago, is yet to return with an $8bn deal across loan and bond markets that was postponed a couple of weeks ago, according to bankers...
...Then after Pershing Square gained a whopping 40 per cent in 2014, it subsequently suffered a string of bad years, wrong-footed by big bets on pharmaceutical company Valeant, and Herbalife, the multilevel...
...Mr Thompson got in touch with a former director at Valeant, the pharmaceuticals company where ValueAct was then a shareholder, to ask about their experience with the firm....
...He has had less success in recent years following unsuccessful bets on the pharmaceutical companies Allergan and Valeant....
...It gained notoriety after targeting pharmaceutical company Valeant, which saw its stock price crumble after fears over its accounting practices and heavy debt load....
International Edition